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A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine 
dose administered by the intramuscular route and offers a potential dose-sparing strategy to stretch the limited global IPV supply 
while further improving population immunity. Multiple studies have assessed immunogenicity of intradermal fIPV compared with 
the full intramuscular dose and demonstrated encouraging results. Novel intradermal devices, including intradermal adapters and 
disposable-syringe jet injectors, have also been developed and evaluated as alternatives to traditional Bacillus Calmette–Guérin 
needles and syringes for the administration of fIPV. Initial experience in India, Pakistan, and Sri Lanka suggests that it is opera-
tionally feasible to implement fIPV vaccination on a large scale. Given the available scientific data and operational feasibility shown 
in early-adopter countries, countries are encouraged to consider introducing a fIPV strategy into their routine immunization and 
supplementary immunization activities.
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Providing vaccination through the intradermal route is an effec-
tive means of delivering vaccines due to the high concentration 
of immune cells in the epidermis (outermost layer of skin) [1]. 
Consequently, a lower intradermal dosage of some vaccines can 
potentially induce an equal or even higher immune response 
than a dose that is administered intramuscularly or subcutane-
ously, if administered correctly.
The concept of a reduced—or fractional—dose of inactivated 
poliovirus vaccine (fIPV) through intradermal administra-
tion has been evaluated in a number of clinical trials over the 
past 50 years. A study reported by Jonas Salk in 1953 using the 
first generation of IPV (before enhanced-potency IPV became 
available) concluded that polio vaccination given by both the 
intradermal route (using one sixth to one tenth of the standard 
dose) and intramuscular route demonstrated substantial immu-
nogenicity [2]. Trials conducted between 1957 and 1979 (again 
using the nonenhanced IPV) [3], as well as pilot studies con-
ducted with enhanced IPV in India [4–6] in the 1990s, found 
that, when provided as the primary series or as a booster dose, 
an intradermal fIPV dose of 0.1 mL (one fifth of the full 0.5-mL 
dose) induced a similar immune response as a full intramuscu-
lar dose. Despite these promising results, fIPV was not widely 
adopted except in Denmark, where it was the standard method 
of IPV vaccination in the mid-1950s [3].
In 2012, the World Health Assembly (WHA) endorsed the 
proposed Polio Endgame Strategy, which includes withdrawal 
of the Sabin-virus type 2 antigen—responsible for an estimated 
95% of vaccine-derived cases of polio [7]—by replacing the tri-
valent oral poliovirus vaccine (tOPV) in the routine immuni-
zation schedule with a bivalent vaccine (bOPV) that lacks the 
type 2 Sabin virus. The Endgame Strategy also recommends the 
introduction of at least 1 dose of IPV to mitigate the risk of type 
2 poliovirus resulting from the elimination of this component 
from the oral vaccine. Since the WHA resolution, all countries 
that were solely using OPV have either introduced IPV into 
their routine immunization schedule or decided to introduce 
IPV but have been unable to secure supply. The global demand 
for IPV has therefore substantially increased in just a few years.
At the same time, the WHA requested that the World Health 
Organization (WHO) work with partners and manufacturers 
to “enhance the affordability, effectiveness and accessibility [of 
IPV]” [8]. To fulfill this mandate, WHO has developed a multi-
pronged strategy to reduce the cost of IPV, which includes fIPV 
as one of the most promising approaches [9].
The possibility of using fIPV has recently drawn more atten-
tion after the two global suppliers of WHO-prequalified IPV 
reported significant challenges in scaling up production to meet 
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the new demand, resulting in a >50% reduction in their initial 
supply commitments made in 2014 (for the period 2014–2018). 
In many countries, these constraints have resulted in a delay in 
IPV introduction or stockouts, and they have affected the global 
IPV reserve established for outbreak response and supplemen-
tary immunization campaigns [10]. Therefore, the adoption of 
fIPV as an antigen-sparing technique could potentially be a key 
strategy for countries to stretch the limited supply of IPV while 
still ensuring high population immunity against polio.
Furthermore, even after polio eradication is achieved world-
wide, countries will need to maintain population immunity 
against possible undetected polio transmission and accidental 
release of poliovirus from laboratories or vaccine production 
facilities [11]. Following eradication, countries will need to stop 
using OPV entirely due to the risk of vaccine-derived poliovirus 
emergence, possibly leading to endemic transmission. They will 
thus have to rely solely on IPV, further increasing the mid- to 
long-term demand for this vaccine. The fIPV strategy may pro-
vide an affordable solution to meet this increased demand for 
IPV in the post-OPV era.
In this context, we provide an overview of (1) the recent sci-
entific literature on the use of fIPV for the primary series (either 
alone or in combination with OPV) and as a booster dose; (2) 
the development of new, improved devices for intradermal 
delivery of vaccines; and (3) the regulatory and operational 
aspects of using fIPV, including recent field experience.
SUMMARY OF THE SCIENTIFIC EVIDENCE
Studies of Fractional Inactivated Poliovirus Vaccine Used in the Primary 
Vaccination Series
Humoral Immune Responses
Humoral immunity (antibody response) protects an individual 
from paralytic disease. A series of clinical studies, many conducted 
within the past 5 years, have evaluated the humoral immunity of 
fIPV (using 0.1 mL, one fifth of the full 0.5-mL dose) adminis-
tered intradermally through a variety of vaccine delivery devices 
(eg, Bacillus Calmette–Guérin [BCG] needles and syringes, hol-
low microneedles, needle-free jet injectors) compared with a full 
intramuscular dose when provided as primary vaccination in a 2- 
or 3-dose series using different vaccination schedules. These stud-
ies—conducted in Cuba [12, 13], Oman [14], Philippines [15], 
and Bangladesh [16]—evaluated immunogenicity by examining 
seroconversion rates and antibody levels following vaccination.
The studies found that cumulative seroconversion rates 
(a ≥4-fold increase over the expected decline in maternally 
derived antibody titers) for all polio serotypes following the 
complete vaccination series were comparable between the fIPV 
and intramuscular IPV groups when there was less interference 
with maternal antibody (that is, when the first dose was given 
at or after 2 months of age). On the other hand, the results were 
varied when the vaccination series started earlier (such as at 6 
weeks of age). The Philippines study showed equivalent immu-
nogenicity between fIPV and intramuscular IPV when each 
vaccine was administered at 6, 10, and 14 weeks of age [15]. 
However, studies in Cuba (using the same schedule of immuni-
zation at 6, 10, and 14 weeks) and in Bangladesh (using a 2-dose 
schedule at 6 and 14 weeks) showed slightly lower cumulative 
seroconversion rates in the fIPV group than in the intramuscu-
lar group [12, 16].
Because most OPV-using countries have added a single dose 
of IPV in their primary vaccination series, it is also useful to 
compare the immunogenicity of 2 fIPV doses with that of a sin-
gle full intramuscular dose. In all studies, 2 fIPV doses (ie, total 
of 0.2 mL) resulted in substantially higher seroconversion rates 
for all poliovirus serotypes than a single intramuscular dose [12, 
13, 14, 16, 17] (Figure 1).
Examining the median antibody levels by vaccination group 
in these studies, a single fIPV dose of 0.1 mL resulted in lower 
median neutralizing antibody titers (MATs) for any of the 
3 poliovirus serotypes compared with a single full (0.5  mL) 
intramuscular dose. However, the MATs in the fIPV groups 
were all >1:8 dilution, indicating protection against paralytic 
disease. Thus, the difference in antibody levels between the 
fIPV and intramuscular groups was not considered clinically 
relevant [18]. In addition, median antibody levels following 
2 fIPV doses were significantly higher in all studies than the 
titers following a single intramuscular dose for any of the 
serotypes.
After reviewing these data in October 2016, WHO’s Strategic 
Advisory Group of Experts on Immunization (SAGE) reiterated 
the recommendation it first made in April 2016 that countries 
should start preparing for a 2-dose fIPV schedule (eg, at 6 and 14 
weeks of age), in lieu of a single intramuscular dose at 14 weeks 
[11]. Prior to the SAGE recommendation, 8 states in India and 
the country of Sri Lanka had already made this change to their 
immunization schedule. India will expand the use of fractional 
doses to an additional 8 states in August 2016 and to all 36 states 
in April 2017. In addition, Bangladesh has decided to introduce 
fIPV in their routine schedule in 2017 [19].
Mucosal Immune Responses
Although humoral immunity is important to prevent paralytic 
disease, mucosal immunity through the intestinal tract is essen-
tial to prevent excretion and transmission of the virus. Some 
of the studies mentioned above compared intestinal immunity 
induced by fractional versus full-dose IPV—with inconclusive 
results.
In the Oman study, infants received either a full intramuscu-
lar or intradermal fIPV at 2, 4, and 6 months of age, followed 
by a challenge dose of monovalent OPV type 1 (mOPV1) at 
7  months [14]. Seven days after the challenge dose, the per-
centage of children shedding type 1 poliovirus was significantly 
higher in the fractional-dose group than in the full-dose group 
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(74.8% vs 63.1%). In the Bangladesh study, a challenge dose of 
trivalent OPV was given to subjects at 18 weeks following vac-
cination with either fractional or full doses of IPV at 6 and 14 
weeks [16]. Seven days after the challenge, viral excretion rates 
in the intramuscular arm and the fIPV arm were, respectively, 
49.4% and 48.3% against type 1, 57.1% and 65.6% against type 
2, and 32.1% and 42.4% against type 3. These differences were 
not statistically significant, suggesting that fractional intrader-
mal doses were as good as full intramuscular doses of IPV in 
inducing intestinal immunity.
Duration of Seroprotection
A study in the Philippines compared seroprotection of frac-
tional and full-dose IPV 12 to 15 months after infants received 
the primary series with 1 of these formulations at 6, 10, and 14 
weeks [15]. Seroconversion rates for all poliovirus types were 
similar in the 2 groups: for example, 84% for type 2 poliovirus in 
the fIPV group versus 88% in the full intramuscular dose group. 
Geometric mean titers (GMTs) for type 2 poliovirus were 94.0 
among infants in the fIPV group and 132.5 in the full-dose 
group. These results suggest that immunity induced by fIPV 
likely lasts as long as immunity induced by full-dose IPV.
Using Fractional Inactivated Poliovirus Vaccine to Boost Immunity
Studies assessing the ability of fIPV to boost immunity among 
children who had previously received OPV have been con-
ducted in India [20], Cuba [21], and Gambia [22]. These studies 
suggest that intradermal fIPV has less ability to boost antibody 
levels than the regular intramuscular dose, especially when the 
baseline titers are already high. However, recent studies among 
adults in Cuba [23] and among OPV-primed children aged 10 
to 12 years in Sri Lanka (O. Mach, WHO, personal communica-
tion) found that an fIPV dose was as effective as a full intramus-
cular dose in boosting both humoral and mucosal immunity 
among OPV-immunized individuals. This suggests that fIPV 
through the intradermal route is as effective as IPV adminis-
tered intramuscularly in boosting individuals with no or lower 
baseline titers.
Based on this new evidence, the WHO SAGE recommended 
in October 2016 that outbreak response campaigns (to boost 
population immunity) should use only fIPV [11].
Intradermal Injection Devices
One of the challenges with the fIPV strategy is that intradermal 
injections are more complex to administer than intramuscular 
injections. Health workers must be well trained in the tech-
nique, and incorrect administration can lead to adverse events. 
However, new injection technologies have recently been devel-
oped and registered as alternatives to the conventional BCG 
needle and syringe to facilitate intradermal delivery of vaccines, 
including fIPV. These include several needle-free devices (eg, 
disposable-syringe jet injectors) and needle-based devices (eg, 
hollow microneedles and adapters that attach to the hub of the 
intradermal needle and syringe) (Table 1).
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Figure 1. Comparison of seroconversion of 2 intradermal fractional inactivated poliovirus vaccine doses with 1 full intramuscular dose across 5 studies.
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Several of these devices have been tested in clinical studies 
comparing intradermal fIPV with intramuscular IPV, includ-
ing the disposable-syringe jet injector Tropis (PharmaJet) in 
Gambia [22] and the MicronJet 600 (NanoPass) disposable hol-
low microneedle in Bangladesh [16] and in the United States 
[24]. These studies have demonstrated the safety and injection 
quality of these devices.
Other studies have assessed fIPV administration with novel 
intradermal devices alongside the conventional BCG needle 
and syringe, allowing a comparison of immunogenicity. In a 
recent study in Cuba [21], fIPV administered through 2 nee-
dle-free disposable-syringe jet injectors—Tropis and Biojector 
2000 (Bioject)—achieved similar immune responses against all 
3 poliovirus serotypes as those obtained with the BCG needle 
and syringe. However, a third jet injector—ID Pen (Bioject)—
performed significantly worse, with seroconversion rates for 
type 2 poliovirus of 22.6% compared with 49%–54% for the 
BCG needle and 2 other injectors. Mild local reactions such as 
erythema, induration (hardening of the skin), and infiltration 
(swelling) were more frequent with all of the novel injectors 
than with the BCG needle and syringe. Healthcare workers pre-
ferred administering the vaccine with the disposable-syringe jet 
injectors over the traditional BCG needle and syringe because 
of the ease of administration with these devices.
In the Gambia study [22], OPV-immunized infants who 
had received a single dose of measles-rubella (MR) or yel-
low fever vaccine alone or in combination at 9–10 months 
of age (to study any interference between these vaccines and 
IPV) were given 1 dose of IPV 4–6 weeks later. The chil-
dren were randomly assigned to receive the vaccine either 
via the intramuscular or intradermal route and by needle 
and syringe (both intramuscular and intradermal routes) or 
by disposable-syringe jet injectors (Stratis for intramuscu-
lar and Tropis for intradermal, both made by PharmaJet). 
Whereas both intradermal needle/syringe and intradermal jet 
injector groups had high seroprevalence rates (>93%) for all 
polio serotypes 28 days after the IPV dose, the median anti-
body levels in the intradermal jet injector (Tropis) group were 
identical for types 1 and 2 but lower for type 3. There were no 
differences in rates of local reactions (eg, erythema, infiltra-
tion, or tenderness) or systemic reactions (eg, fever, vomiting, 
excessive crying, poor appetite, diarrhea) between the groups 
vaccinated with a needle and syringe (either by intramuscu-
lar or intradermal administration) and those vaccinated using 
disposable-syringe jet injectors.
Another clinical study is currently taking place in Gambia to 
evaluate both the immunogenicity and the programmatic feasi-
bility for use in immunization campaigns of a revised version of 
the Tropis device in comparison with other intradermal injec-
tion methods (needle and syringe, intradermal adapter).
Finally, a recent study in Pakistan compared the usability and 
immune response of fIPV using the intradermal adapter (West 
Pharmaceutical Services) and a novel intradermal syringe (Star 
Syringe) with the BCG needle and syringe [25]. It showed that 
the intradermal adapter induced a similar immune response (ie, 
seroconversion plus boosting) as the BCG needle and syringe 
and that vaccinators had a strong preference for intradermal 
adapters. The study also demonstrated that fIPV administration 
using either device was feasible and safe to use in both health 
center and campaign settings.
Table 1. Selected Devices for Intradermal Administration of Vaccines
Device (supplier) Description
Registered  
for use
Doses  
per viala
Availability of clini-
cal data for IPV
Availability of clin-
ical data for other 
vaccines
ID Adapter (West 
Pharmaceutical 
Services)
Plastic adapter that fits onto an autodisable 
intradermal needle and syringe that is 
provided with the device
Yes 5 Yes No
Star ID Syringe (Star) Needle/syringe with a short minineedle and 
90-degree injection angle, filled with an 
integrated plastic spike
No 5 Yes
(prototype)
No
MicronJet 600 
(NanoPass)
Hollow microneedle hub that can be 
attached to a luer syringe following filling 
with a separate needle
Yes 3 Yes Yes
Tropis (PharmaJet) Needle-free jet injector that uses a sterile 
single-dose syringe and pressurized liquid 
stream instead of needle
Yes 5 Yes Yes
ID Pen (Bioject) Needle-free jet injector developed as an 
alternative to Bioject’s gas-powered 
Biojector2000 device that is optimized for 
intradermal administration in low-resource 
settings (manually powered, intradermal 
only)
No 4 Yes Yes
Abbreviations: ID, intradermal; IPV, inactivated poliovirus vaccine.
aNumber of 0.1-mL doses obtained from each device from a model 0.5-mL vial [39].
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Intradermal delivery devices have also been positively eval-
uated in clinical studies of a number of other vaccines. These 
include influenza vaccination studies using the MicronJet 600 
jet injector [26–29]; studies of various investigational nucleic 
acid vaccines (eg, dengue, herpes simplex virus, human immu-
nodeficiency virus) delivered by the Biojector 2000 [30–32]; 
BCG vaccination with the Bioject ID Pen [33]; and studies of 
human papillomavirus (HPV), dengue, rabies, and various 
anticancer vaccines using the Tropis jet injector (C. Cappello, 
PharmaJet, personal communication). Intradermal devices 
have also been found to be preferred by parents and to cause less 
crying in infants compared with IPV delivery by intramuscular 
and intradermal injection with needle and syringe [12, 14, 25].
Upon review of available data, the Strategy Committee of 
the Global Polio Eradication Initiative (GPEI) endorsed in 
November 2015 the procurement of the intradermal adapter 
produced by West Pharmaceuticals and the Tropis (PharmaJet) 
disposable-syringe jet injector for the WHO IPV stockpile for 
polio outbreak response. These intradermal delivery devices 
would cost $0.50–$0.85 per injection, which is considerably 
more than conventional autodisable (AD) syringes ($0.04 
per piece). However, a recent analysis conducted by PATH 
suggested that the dose sparing of fIPV can potentially offset 
the increased cost of these devices (Table 2). Further data are 
needed on operational costs, such as training health workers in 
intradermal administration, to expand on this initial cost anal-
ysis and draw firmer conclusions.
OPERATIONAL ASPECTS OF USING FRACTIONAL 
INACTIVATED POLIOVIRUS VACCINE
Regulatory Considerations Concerning the Vaccine
Currently, the use of fIPV administered intradermally is con-
sidered an off-label use, and the IPV manufacturers do not 
intend to license their products for intradermal administration 
in the foreseeable future. However, it is not uncommon for pub-
lic health authorities, such as the SAGE or national immuni-
zation technical advisory groups, to make recommendations 
that differ from indications on the vaccine product, especially 
in emergency situations, such as during yellow fever outbreaks 
[34]. Countries should therefore make decisions concerning the 
introduction of fIPV into their immunization schedule based 
on an independent scientific assessment of available clinical 
study data [11].
Regulatory Considerations for Intradermal Injection Devices
The use of intradermal devices requires a separate regulatory 
clearance (eg, 510(k) in the United States and CE Mark in the 
European Union), depending on the country of use. The US Food 
and Drug Administration has recently added a new requirement 
that, for vaccines to be relabeled for use with disposable-syringe 
jet injectors, noninferiority clinical studies of the specific vac-
cine product using these devices must take place, in addition to 
the 510(k) clearance for the jet injector itself. The vaccine label 
can either indicate delivery by jet injection as a class of devices, 
enabling any 510(k)-cleared jet injector to be used, or specify 
a particular device [35]. The position of other national regula-
tory authorities on the requirement for label change specifically 
for jet injectors is less well defined. In 2013, WHO prequalified 
PharmaJet’s Stratis injector (used for intramuscular or subcu-
taneous injection) and requested that a jet injector “be used 
according to the label to deliver only those medications and vac-
cines that have been approved by the relevant Authorities” [36].
Integrity of Vaccine Vial Stoppers
Using multidose vials involves piercing the vial stopper repeat-
edly with a BCG needle and syringe to draw out each dose. 
Table 2. Estimated Costs of Materials for Inactivated Polio Vaccination Per Immunized Child
Options IPV Device
Cost per child immunized (USD)
Delivery device Total cost (vaccine + device)
Current strategy Sanofi 10-dose vial (1 full dose) IM AD needle and syringe 0.04 1.1
BBio 5-dose vial (1 full dose) IM AD needle and syringe 0.04 2.3
Proposed alternatives BBio 5-dose vial (2 fractional doses) ID AD needle and syringe 0.08 1.0
ID adapter 1.1 2.0
Jet injector 1.6 2.5
BBio 1-dose vial (2 fractional doses) ID AD needle and syringe 0.08 1.4
ID adapter 1.1 2.4
Jet injector 1.7 3.0
Key assumptions in cost estimates include the following:
Cost of vaccine per intramuscular dose: Sanofi 10-dose vial—$0.82; BBio 5-dose vial—$1.90; BBio 1-dose vial—$2.80.
Vaccine wastage rate: Single dose vial—5%; 5-dose vial—15%; >10 dose vial—20%.
Cost of devices: Intramuscular or intradermal autodiable needle and syringe—$0.04; Intradermal adapter with autodisable syringe—$0.55; Jet injector (including a needle-free syringe, filling 
adapter and device)—$0.75–$0.85 per injection.
Total uses per jet injector: approximately 1000, based on preliminary calculations of potential fractional inactivated poliovirus vaccine delivery volumes for 2 years during inactivated poliovirus 
vaccine supply shortage. Lifespan of device is ≥20 000 uses, but this could span many years in a routine immunization setting.
Abbreviations: AD, autodisable; BBio, Bilthoven Biologicals; ID, intradermal; IM, intramuscular; IPV, inactivated poliovirus vaccine.
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Fractional IPV significantly increases the number of pierc-
ings (ie, 5-fold), which could potentially compromise the 
integrity of the vial stopper. PATH recently conducted two 
types of tests of vial stoppers used for two WHO-prequalified 
IPVs following repeated piercing with a 27-gauge needle [37]. 
Self-sealing tests—in which the stoppers were pierced up to 
100 times and the vials then submerged in methylene blue 
solution under a vacuum—did not demonstrate any closure 
failures with either stopper. Fragmentation tests—in which 
stoppers were pierced and the contents of the vial were then 
filtered and the visible particles counted—found that the fre-
quency of fragments produced after up to 50 piercings met 
the target rate of <10% of punctures resulting in particle 
formation.
Operational Feasibility of Using Fractional Inactivated Poliovirus Vaccine
Experiences in several states of India and in Sri Lanka have 
demonstrated that administering fIPV intradermally in a rou-
tine immunization setting can be done safely and effectively, 
provided there is a proper training program and supervision 
strategy.
The operational feasibility of administering fIPV doses 
during mass vaccination campaigns in response to out-
breaks has also been demonstrated recently in India and 
Pakistan (both using a traditional BCG needle and syringe). 
An outbreak response campaign conducted in June 2016 in 
Hyderabad, India (in the state of Telangana, where routine 
immunization using fIPV was already taking place) demon-
strated the feasibility of successfully planning and implement-
ing a mass vaccination campaign using fIPV in a short period 
of time [38]. Within 14  days of the discovery of circulating 
vaccine-derived polio type 2 virus, >311 000 children aged 6 
weeks to 3 years were vaccinated over a 6-day period using a 
fixed-site approach. Bleb formation (a small blister indicative 
of a correct intradermal injection) was observed in 93% of chil-
dren, and no major safety concerns were found, nor was there 
leakage or visible damage to the vaccine vial cap or septum 
after repeated punctures. A postcampaign survey estimated a 
coverage rate for fIPV of 94% of target-age children. Another 
outbreak response campaign using fIPV was conducted among 
>200 000 children aged 4–23 months in Hyderabad, Pakistan, 
in October and November 2016.
To date, the only vaccine wastage data yet available for fIPV 
vaccination come from the mass vaccination campaigns con-
ducted in India and the study conducted in Karachi, Pakistan, 
in 2016 [25]. In Hyderabad, India, where 10 full-dose IPV vials 
were used to give 50 doses of fIPV, a median of 48 doses (range 
= 41–50) were obtained per vial, for a median wastage rate of 
4% [38]. In the Karachi study, where 5-dose IPV vials were used 
to obtain 25 doses of intradermal fIPV, the reported wastage 
rate was 10% using intradermal adapters and 6% using BCG 
needles and syringes [25].
CONCLUSIONS
Considerable scientific evidence is available to support the use 
of intradermal fIPV for both routine and supplementary immu-
nization activities. In addition, the development of a range of 
intradermal devices, such as needle-free jet injectors and nee-
dle adapters, show promise for furthering the use of fIPV by 
improving its usability and the ease of administration in the 
field. Given the severely limited global supply of IPV, countries 
are strongly encouraged to consider assessing the program-
matic feasibility and trade-offs of introducing IPV using a 
2-fractional-dose strategy through their national immuniza-
tion technical advisory groups or other advisory bodies. This 
option would not only address the immediate IPV shortage but 
also serve as an affordable and immunogenic option for routine 
immunization after global polio eradication has been achieved. 
One possible strategy is to provide 2 fIPV doses beyond early 
infancy (eg, at the same time as diphtheria-tetanus-pertussis 
or measles) because this approach has been shown to result in 
seroconversion rates among children of >90% [13].
Moving forward, further assessments of the ongoing use of 
fIPV (eg, routine immunization in India and Sri Lanka, mass 
vaccination campaigns in Pakistan), as well as more pilot proj-
ects, would be helpful to facilitate country discussions and 
decision making to introduce fIPV. Additional research is also 
desirable to better understand the role of fIPV in inducing 
mucosal immunity and long-term immunity to provide further 
evidence to support the implementation of this strategy.
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